Rest-Of-GCC-Countries Cell Culture Market Size, Share,Trends, Growth Analysis Report, 2031

Name: Rest-Of-GCC-Countries Cell Culture Market Size, Share,Trends, Growth Analysis Report, 2031
Creator: MarketsandMarkets

Overview Request Sample Pages Request Customization Download PDF

You are viewing: Rest Of GCC Countries Cell Culture Market analysis

Part of: Cell Culture Market (Global)

The Rest Of GCC Countries Cell Culture Market was valued at $48.3 Million in 2026 and projected to reach to $69.7 Million by 2031, representing a compound annual growth rate of CAGR 7.6%. Rest Of GCC Countries is emerging as a promising market for cell culture technologies, driven by substantial investments in healthcare modernization and biotechnology development.

Rest Of GCC Countries Cell Culture Market (2026-2031) : Size and Share

CAGR of

USD Million

Rest Of GCC Countries Cell Culture Market Trends and Insights

Rest Of GCC Countries is positioned as a developing hub for biopharmaceutical research and production, driven by increasing investments in healthcare infrastructure and biotechnology capabilities.
By 2031, Rest Of GCC Countries is projected to reach a market size of $69.7 million, representing a compound annual growth rate of 7.6%. Rest Of GCC Countries benefits from regional initiatives promoting life sciences innovation and pharmaceutical manufacturing.
The expansion reflects growing demand for advanced cell culture technologies, including media, sera, and bioreactors, as Rest Of GCC Countries strengthens its position in the broader GCC healthcare ecosystem.
Rest Of GCC Countries' market growth is supported by rising R&D spending and collaborations with international biotech firms seeking regional expansion opportunities..

Key Market Statistics

CAGR (2026-2031) CAGR 7.6%
Market Size, 2026 ~USD 48.3 Million
Forecast, 2031 ~USD 69.7 Million
Country Rest Of GCC Countries

Rest Of GCC Countries Cell Culture Market Overview

Steady Regional Growth :

Rest Of GCC Countries cell culture market is projected to grow from $48.3 million in 2026 to $69.7 million by 2031, representing a robust 7.6% CAGR, outpacing many emerging markets in the region.

Biotech Infrastructure Expansion :

Increasing government investments in healthcare infrastructure and biotechnology capabilities are positioning Rest Of GCC Countries as a developing hub for biopharmaceutical research and production activities.

Regional Market Positioning :

Rest Of GCC Countries represents a strategic emerging market within the GCC bloc, with growing demand for advanced cell culture technologies driven by expanding pharmaceutical and research sectors.

Investment Opportunities :

The 44.4% market expansion over five years indicates significant opportunities for cell culture technology providers and biopharmaceutical companies establishing regional operations in Rest Of GCC Countries.

Rest Of GCC Countries Cell Culture Market Dynamics

The region's commitment to diversifying its economy beyond oil has catalyzed growth in pharmaceutical manufacturing and research capabilities, creating sustained demand for advanced cell culture solutions.
Government initiatives supporting life sciences infrastructure are attracting both domestic and international biopharmaceutical investments. By 2031, Rest Of GCC Countries is expected to establish itself as a regional leader in cell culture applications, with market growth accelerating as local research institutions and pharmaceutical manufacturers scale operations.
The 7.6% CAGR reflects increasing adoption of cell-based therapies, vaccine production, and biopharmaceutical development.
Strategic partnerships with global biotech firms and continued healthcare spending will further strengthen the market's trajectory through the forecast period..

Related Ecosystem

Biotechnology

Top Technologies

Reagents
Polymerase Chain Reaction (PCR)
Stem Cells
Assay Kits
Flow Cytometers

Top Companies

Thermo Fisher Scientific Inc.
Merck KGaA
Danaher Corporation
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.

Key Takeaways

Rest Of GCC Countries cell culture market valued at $48.3 million in 2026, growing to $69.7 million by 2031 at 7.6% CAGR.
Rest Of GCC Countries is emerging as a regional biotech hub with increasing pharmaceutical R&D investments and infrastructure development.
Rest Of GCC Countries demand for cell culture products is driven by vaccine development, biologics manufacturing, and regenerative medicine research.
Rest Of GCC Countries market growth is supported by government initiatives, international partnerships, and rising healthcare spending across the region.

Cell Culture Market Report Scope

Report Metric	Details
Base Year	2026
Fastest Growing Segment	TISSUE ENGINEERING & REGENERATIVE MEDICINE (Application)
Forecast Period	2026�2031
Growth Rate	CAGR of 12.1% from 2026 to 2031
Largest Segment	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User)
Market Size Base Year (Billions)	~USD 33 (2026)
Revenue Forecast (Billions)	~USD 58.42 (2031)
Segments Covered	Product, Type, Application, End User

Rest Of GCC Countries Cell Culture Market Report Segmentation

4 segment dimensions are covered across the global market.

By Product

Consumables
Equipment

By Type

Adult Bovine Sera
Antibiotics/Antimycotics
Attachment & Matrix Factors
Autoclaves
Balanced Salt Solutions
Bhk Media
Bioreactors
Biosafety Cabinets
Buffers & Chemicals
Carbon Dioxide Incubators
Cell & Gene Therapy
Cell Counters
Cell Dissociation Reagents
Cell Factory Systems/Cell Stacks
Centrifuges
Chemically-Defined Media
Cho Media
Classical Media & Salts
Contamination Detection Kits
Cryoprotective Reagents
Cryostorage Systems
Fetal Bovine Sera
Filtration Systems
Flasks
Growth Factors
Hek 293 Media
Media
Microscopes
Monoclonal Antibody Production
Multiwell Plates
Other Animal Sera
Other Consumables & Accessories
Other Media
Other Reagents
Other Serum-Free Media
Other Supporting Equipment
Other Therapeutic Protein Production
Other Tissue Engineering & Regenerative Medicine Applications
Petri Dishes
Reagents
Refrigerators & Freezers
Roller/Roux Bottles
Sera
Sera, Media, And Reagents
Serum-Free Media
Serum-Free Stem Cell Media
Specialty Media
Stem Cell Culture Media
Storage Equipment
Supplements
Supporting Equipment
Vaccine Production
Vero Cell Media
Vessels

By Application

Biopharmaceutical Production
Diagnostics
Drug Screening & Development
Other Applications
Tissue Engineering & Regenerative Medicine

By End User

Academic & Research Institutes
Hospitals & Diagnostic Laboratories
Other End Users
Pharmaceutical & Biotechnology Companies

Target Audience

Biopharmaceutical Manufacturers : Need detailed Rest Of GCC Countries market data to evaluate expansion opportunities, assess local demand for cell culture technologies, and plan manufacturing facility investments in the region.
Cell Culture Technology Providers : Require specific market intelligence on Rest Of GCC Countries to develop targeted sales strategies, identify key customer segments, and customize product offerings for regional biotech growth.
Healthcare Investment Firms : Seek comprehensive Rest Of GCC Countries market analysis to evaluate investment opportunities in biotech infrastructure, pharmaceutical companies, and cell culture solution providers in the region.
Research Institution Leaders : Need Rest Of GCC Countries market forecasts to justify funding requests, plan laboratory expansions, and identify collaboration opportunities with emerging regional biotech ecosystems.
Government & Policy Makers : Require Rest Of GCC Countries market data to inform healthcare policy, biotechnology incentive programs, and infrastructure development initiatives supporting regional pharmaceutical advancement.

Key Companies in the Rest Of GCC Countries Cell Culture Market

Company	HQ	Ownership	Strongest segments
PATHEON INC	Netherlands	Private Company	Drug product services (oral, sterile, packaging, lifecycle management),Pharmaceutical development services (formulation, analytical, clinical supply),Drug substance services (small-molecule and biologics APIs),
BIOMERIEUX S.A.	France	Public Company	Clinical microbiology (culture media, VITEK, blood culture, ID/AST),Molecular and syndromic diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and CLIA (VIDAS, Hybiome),
SIGMA-ALDRICH CORPORATION	United States	Private Company	Chemicals, biochemicals, and analytical reagents,Cell culture media, critical raw materials, and bioprocess solutions,Filtration, water purification, and labware,
HI-MEDIA	France	Public Company	In-content native and integrated formats,Geo-marketing and location-based solutions,Managed campaign and data-driven services,
REPLIGEN CORPORATION	United States	Public Company	Filtration and cell retention (XCell ATF, KrosFlo, TangenX, ProConnex TFDF),Chromatography (OPUS columns, KRM systems, resins, ELISA kits),Process analytics and PAT (PATsmart suite, SoloVPE/FlowVPE, ZipChip, REBEL),
QIAGEN NV	Netherlands	Public Company	Sample technology consumables and instruments,Immune response and infectious disease assays,Oncology and sexual & reproductive health assays,
QUIDEL CORPORATION	United States	Public Company	Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care,
FLUOR CORPORATION	United States	Public Company	Energy Solutions,Urban Solutions,Mission Solutions,
TECHNICOLOR SA	France	Public Company	Broadband gateways and routers (fiber, xDSL, cable),Wi-Fi extenders, Wi-Fi XL, homeware and in-home networking,Video set-top boxes, dongles, smart media devices,
EIKEN CHEMICAL CO., LTD.	Japan	Public Company	Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents (clinical),Urinalysis test strips and analyzers,
MAXCYTE, INC	United States	Public Company	ExPERT Instruments (ATx, STx, GTx, VLx),Consumables (Processing Assemblies, Buffers, Accessories),Licensing and Technology Access,
THERMO FISHER SCIENTIFIC INC.	United States	Public Company	Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
DANAHER CORPORATION	United States	Public Company	Biotechnology (bioprocessing and related solutions),Life Sciences tools and genomic medicine,Diagnostics,
MERCK KGAA	Germany	Public Company	Life Science (tools, consumables, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, equipment),
SARTORIUS AG	Germany	Public Company	Bioprocess solutions (bioreactors, cell culture, fluid and process chromatography/filtration),Lab products and services (filtration, water systems, weighing, pipettes, microbiological testing),Analytical and PAT solutions (BLI, cytometry screening, live-cell imaging, SPR, data analytics),
CORNING INCORPORATED	United States	Public Company	Optical communications (fiber, cable, hardware, connectors),Display glass substrates (LCD/OLED),Specialty materials and optics,
FUJIFILM HOLDINGS CORPORATION	Japan	Public Company	Healthcare (medical systems, CDMO, pharma, regenerative medicine, cosmetics/supplements),Electronics (display/touch panels, semiconductor and display materials, storage media, industrial equipment, fine chemicals),Business Innovation (office equipment, document solutions, graphic communications, industrial inkjet),
BD	United States	Public Company	Medical Essentials (syringes, needles, vascular access, sharps, enteral),Connected Care (infusion pumps, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, related solutions),
EPPENDORF SE	Germany	Private Company	Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
LONZA	Switzerland	Public Company	Integrated Biologics (mammalian DS/DP platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs/bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
GETINGE	Sweden	Public Company	Acute Care Therapies (ECMO, ventilation, monitoring, ICU infrastructure, drainage),Surgical Workflows (OR equipment, anesthesia, OR integration, sterile supply management),Life Science (sterilization, biocontainment, bioprocess, labware cleaning, vivarium),
AGILENT TECHNOLOGIES, INC.	United States	Public Company	Life Sciences and Diagnostics Markets,Agilent CrossLab (Services, Consumables, Software),Applied Markets (GC, MS, Spectroscopy, Vacuum, Remarketed),
BIO-TECHNE	United States	Public Company	Protein Sciences (reagents and proteomic tools),Diagnostics products and controls,Genomics and spatial biology,

PATHEON INC

Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.

BIOMERIEUX S.A.

bioM�rieux S.A. is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics and microbiology testing solutions.

SIGMA-ALDRICH CORPORATION

Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees, supplying research chemicals and biochemicals globally.

HI-MEDIA

HI-MEDIA is a French public company founded in 1996 with 29 employees that manufactures culture media and laboratory reagents for microbiology.

REPLIGEN CORPORATION

Repligen Corporation is a United States-based public company founded in 1981 with 2,000 employees providing bioprocessing solutions and chromatography products.

QIAGEN NV

QIAGEN NV is a Netherlands-based public company founded in 1984 with 5,500 employees specializing in molecular diagnostics and sample preparation technologies.

QUIDEL CORPORATION

Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees developing rapid diagnostic testing solutions.

FLUOR CORPORATION

Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees providing engineering, procurement, and construction services.

TECHNICOLOR SA

Technicolor SA is a France-based public company founded in 1985 with 1,552 employees offering media and entertainment technology services.

EIKEN CHEMICAL CO., LTD.

Eiken Chemical Co., Ltd. is a Japan-based public company founded in 1939 with 696 employees manufacturing diagnostic reagents and laboratory chemicals.

MAXCYTE, INC

MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees developing cell engineering and electroporation technologies.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical instruments globally.

DANAHER CORPORATION

Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating diversified businesses in life sciences, diagnostics, and environmental solutions.

MERCK KGAA

Merck KGaA is a Germany-based public company founded in 1668 with 59,077 employees providing pharmaceuticals, chemicals, and life science products and services.

SARTORIUS AG

Sartorius AG is a Germany-based public company founded in 1870 with 14,242 employees manufacturing laboratory and bioprocess equipment for the life sciences industry.

CORNING INCORPORATED

Corning Incorporated is a United States-based public company founded in 1851 with 67,200 employees producing specialty glass, ceramics, and optical products.

FUJIFILM HOLDINGS CORPORATION

Fujifilm Holdings Corporation is a Japan-based public company founded in 1934 with 73,526 employees operating in imaging, information, and document solutions.

BD

BD is a United States-based public company founded in 1897 with 72,000 employees manufacturing medical devices, diagnostics, and life science tools.

EPPENDORF SE

Eppendorf SE is a Germany-based private company founded in 1945 with 4,358 employees manufacturing laboratory equipment and consumables for life sciences research.

LONZA

Lonza is a Switzerland-based public company founded in 1897 with 20,000 employees providing pharmaceutical and biotechnology manufacturing services and products.

GETINGE

Getinge is a Sweden-based public company founded in 1904 with 11,754 employees manufacturing medical devices and systems for healthcare and life sciences.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.

BIO-TECHNE

Bio-Techne is a United States-based public company founded in 1976 with 3,100 employees providing protein reagents, antibodies, and analytical instruments for life sciences research.

Reasons to Buy this Report

Regional Market Sizing : Obtain precise market valuation for Rest Of GCC Countries ($48.3M in 2026, $69.7M in 2031) to accurately assess investment potential and competitive positioning in this emerging biotech hub.
Growth Trajectory Analysis : Understand the 7.6% CAGR specific to Rest Of GCC Countries, enabling strategic planning for market entry, expansion, and resource allocation in this high-growth regional segment.
Infrastructure Development Insights : Gain intelligence on healthcare infrastructure investments and biotechnology capability expansion driving cell culture adoption specifically in Rest Of GCC Countries markets.
Competitive Opportunity Assessment : Identify market gaps and growth opportunities unique to Rest Of GCC Countries before competitors establish dominance in this developing pharmaceutical and research hub.
Investment Decision Support : Make data-driven decisions on facility location, partnership development, and product localization strategies tailored to Rest Of GCC Countries' specific market dynamics and growth potential.

Frequently asked questions

What is the current market size of cell culture in Rest Of GCC Countries?

Rest Of GCC Countries cell culture market is estimated at $48.3 million in 2026.

What is the projected market size for Rest Of GCC Countries by 2031?

Rest Of GCC Countries cell culture market is forecast to reach $69.7 million by 2031.

What is the CAGR for Rest Of GCC Countries cell culture market?

Rest Of GCC Countries cell culture market is expected to grow at a CAGR of 7.6% from 2026 to 2031.

What factors are driving growth in Rest Of GCC Countries?

Rest Of GCC Countries growth is driven by increased R&D investments, government biotech initiatives, vaccine development programs, and international pharmaceutical partnerships.

Which cell culture products are most in demand in Rest Of GCC Countries?

Rest Of GCC Countries shows strong demand for cell culture media, sera, bioreactors, and consumables used in biologics manufacturing and vaccine production.

RESEARCH METHODOLOGY

This research study relied extensively on secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell culture market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell culture market. The secondary sources used for this study include World Health Organization (WHO), Food and Drug Administration, American Society for Cell Biology (ASCB), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Centers of Disease Control and Prevention (CDC), International Serum Industry Association (ISIA), Pharmaceutical Research and Manufacturers of America (PhRMA), International Society for Vaccines (ISV), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Society for In Vitro Biology (SIVB), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), American Type Culture Collection (ATCC), and the Alliance for Regenerative Medicine (ARM); corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Cell Culture Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell culture market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Cell Culture Market : Top-Down and Bottom-Up Approach

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Cell culture refers to the removal of cells from an animal or plant and their subsequent growth in an artificial environment under controlled conditions. It is a process of growing cells outside their natural environment, typically in a laboratory setting. This technique allows researchers to study cells in a controlled environment, providing insights into their behavior, growth, metabolism, and response to various stimuli.

The scope of this report includes products such as equipment and consumables, such as media, sera, reagents, vessels, bioreactors, storage equipment, and other cell culture-supporting equipment that support the cell culture process.

Key Stakeholders

Cell Culture Equipment and Reagents Manufacturers
Analytical and Life Science Instrumentation Companies
Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
Life Science Companies
Venture Capitalists and Investors
Government Organizations
Private Research Firms
Contract Research Organizations (CROs)
Hospitals and Diagnostic Laboratories
Cell Banks

Report Objectives

To define, describe, and forecast the global cell culture market based on product, application, end user, and region
To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cell culture market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the cell culture market
To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the cell culture market

Available customizations:

Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:

Portfolio Analysis

Product Matrix, which gives a detailed comparison of the product portfolios of the top five companies.

Regional Analysis

A further breakdown of the Rest of Europe cell culture market, by country
A further breakdown of the Rest of Asia Pacific cell culture market, by country
A further breakdown of the Rest of Latin America cell culture market, by country

Get the Full Cell Culture Market Report

Full forecast, segment splits, and company analysis for all Cell Culture Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies

Market Size in	USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered	Value (USD MN)